ATE526985T1 - Aus interleukin-1-beta abgeleitetes peptid und therapeutische verwendung davon - Google Patents

Aus interleukin-1-beta abgeleitetes peptid und therapeutische verwendung davon

Info

Publication number
ATE526985T1
ATE526985T1 AT03740584T AT03740584T ATE526985T1 AT E526985 T1 ATE526985 T1 AT E526985T1 AT 03740584 T AT03740584 T AT 03740584T AT 03740584 T AT03740584 T AT 03740584T AT E526985 T1 ATE526985 T1 AT E526985T1
Authority
AT
Austria
Prior art keywords
gln
cytokine
beta
microg
residues
Prior art date
Application number
AT03740584T
Other languages
English (en)
Inventor
Jean-Francois Zagury
Original Assignee
Vaxconsulting
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Vaxconsulting filed Critical Vaxconsulting
Application granted granted Critical
Publication of ATE526985T1 publication Critical patent/ATE526985T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/521—Chemokines
    • C07K14/523—Beta-chemokines, e.g. RANTES, I-309/TCA-3, MIP-1alpha, MIP-1beta/ACT-2/LD78/SCIF, MCP-1/MCAF, MCP-2, MCP-3, LDCF-1, LDCF-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/485—Epidermal growth factor [EGF], i.e. urogastrone
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/495—Transforming growth factor [TGF]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/525—Tumour necrosis factor [TNF]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/5406—IL-4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/5409—IL-5
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/5412—IL-6
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/5428—IL-10
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/5434—IL-12
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/5437—IL-13
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/5443—IL-15
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/545—IL-1
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/555—Interferons [IFN]
    • C07K14/56—IFN-alpha
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/555—Interferons [IFN]
    • C07K14/57—IFN-gamma
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2299/00—Coordinates from 3D structures of peptides, e.g. proteins or enzymes

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Toxicology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pain & Pain Management (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Rheumatology (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
AT03740584T 2002-04-10 2003-04-09 Aus interleukin-1-beta abgeleitetes peptid und therapeutische verwendung davon ATE526985T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR0204464A FR2838444B1 (fr) 2002-04-10 2002-04-10 Nouveaux peptides et leur application en therapeutique
PCT/FR2003/001120 WO2003084979A2 (fr) 2002-04-10 2003-04-09 Peptides et leur application en therapeutique

Publications (1)

Publication Number Publication Date
ATE526985T1 true ATE526985T1 (de) 2011-10-15

Family

ID=28459716

Family Applications (1)

Application Number Title Priority Date Filing Date
AT03740584T ATE526985T1 (de) 2002-04-10 2003-04-09 Aus interleukin-1-beta abgeleitetes peptid und therapeutische verwendung davon

Country Status (20)

Country Link
US (6) US7393523B2 (de)
EP (3) EP1492814B1 (de)
JP (1) JP2005530723A (de)
KR (1) KR101101004B1 (de)
CN (1) CN1649898A (de)
AT (1) ATE526985T1 (de)
AU (1) AU2003260031B2 (de)
CA (1) CA2480996C (de)
DK (1) DK2314311T3 (de)
ES (2) ES2550030T3 (de)
FR (1) FR2838444B1 (de)
IL (1) IL164429A0 (de)
MA (1) MA27191A1 (de)
MX (1) MXPA04009841A (de)
NZ (1) NZ536351A (de)
RU (1) RU2326125C2 (de)
SI (1) SI2314311T1 (de)
TN (1) TNSN04200A1 (de)
WO (1) WO2003084979A2 (de)
ZA (1) ZA200408451B (de)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7422743B2 (en) * 2000-05-10 2008-09-09 Schering Corporation Mammalian receptor protein DCRS5;methods of treatment
FR2859725B1 (fr) 2003-09-16 2006-03-10 Neovacs Procede a haut rendement pour l'obtention d'anticorps humains neutralisant l'activite biologique d'une cytokine humaine
WO2005084198A2 (en) 2004-02-27 2005-09-15 Vaxconsulting Peptides of il1 beta and tnf alpha and method of treatment using same
BRPI0616446A2 (pt) 2005-09-28 2011-06-21 Cytos Biotechnology Ag composição contendo conjugados de interleucina-1, vacina, uso da vacina, composição farmacêutica, processo para a produção da composição ou da vacina, bem como medicamento
AU2009316076B2 (en) * 2008-11-17 2015-11-19 Kobenhavns Universitet IL-4-derived peptides for modulation of the chronic inflammatory response and treatment of autoimmune diseases
EP2480251B1 (de) 2009-09-21 2025-12-03 Peptinov Trägerkonjugate von il-23-peptiden und deren induzierte antikörper
US9475839B2 (en) 2010-05-11 2016-10-25 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Peptide-based inhibitor of interleukin-10 or interferon-gamma signaling
CN110133300B (zh) * 2012-03-18 2022-02-25 镜株式会社 疾病样品分析装置、分析系统及分析方法
US9376489B2 (en) 2012-09-07 2016-06-28 Novartis Ag IL-18 binding molecules
CA2986494A1 (en) * 2015-06-03 2016-12-08 Affiris Ag Il-23-p19 vaccines
EP3696547B1 (de) * 2017-10-13 2025-08-13 Nibec Co., Ltd. Grp78-abgeleitetes peptid zur identifizierung hochwirksamer stammzellen
PH12021552846A1 (en) * 2019-05-10 2022-10-24 Bimyo GmbH BNIP3 peptides for treatment of reperfusion injury
CN119136838A (zh) 2022-02-28 2024-12-13 特瑞德姆生物科技有限责任两合公司 由至少一种β-葡聚糖或甘露聚糖组成或包含至少一种β-葡聚糖或甘露聚糖的偶联物

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4772685A (en) * 1985-10-02 1988-09-20 Merck & Co., Inc. Immunogenic peptides of human interleukin-1 and the corresponding anti-peptide antibodies
US5013824A (en) * 1985-11-19 1991-05-07 Schering Corporation Human interleukin-4 peptides and conjugates thereof
DE3841761A1 (de) * 1988-12-12 1990-06-13 Basf Ag Neue tnf-peptide
WO1991009059A1 (en) * 1989-12-20 1991-06-27 Schering Corporation Antibody antagonists of human interleukin-4
WO1991014702A1 (en) * 1990-03-19 1991-10-03 Peptide Technology Ltd. Anti-tumour peptides
FR2677654B1 (fr) 1991-06-17 1995-11-17 Pasteur Merieux Serums Vacc Composes a effet immunogene anti-cytokine, a effet immunogene anticytostatique ou a effet vaccinal anti-infection a hiv.
US6117974A (en) * 1991-10-02 2000-09-12 Peptor Limited Libraries of backbone-cyclized peptidomimetics
US5494662A (en) * 1992-04-27 1996-02-27 Ono Pharmaceutical Co., Ltd. Stimulator for bone formation
CA2139571C (en) * 1992-07-07 2006-11-14 Eleanor N. Fish Interferon receptor binding peptides
US5770191A (en) * 1995-05-24 1998-06-23 University Of Florida Active C-terminal peptides of interferon--gamma and their use
US5994292A (en) * 1995-05-31 1999-11-30 The United States Of America As Represented By The Department Of Health And Human Services Interferon-inducible protein 10 is a potent inhibitor of angiogenesis
IT1277926B1 (it) * 1995-09-01 1997-11-12 Angeletti P Ist Richerche Bio Uso di muteine di citochine naturali come immunogeni per la preparazione di composizioni farmaceutiche per curare o prevenire
US6346602B1 (en) * 1997-02-07 2002-02-12 Thomas Jefferson University Peptide mimics of the cytokine receptor common γ chain and methods and compositions for making and using the same
IT1291353B1 (it) * 1997-05-12 1999-01-07 San Raffaele Centro Fond Peptidi con attivita' antivirale
US6440694B1 (en) * 1997-09-30 2002-08-27 Pharmacia & Upjohn Company TNF-related death ligand
JP2002541061A (ja) * 1999-02-08 2002-12-03 メドベット・サイエンス・プロプライエタリー・リミテッド サイトカイン結合ドメイン
WO2000053219A2 (en) * 1999-03-11 2000-09-14 Entremed, Inc. Compositions and methods for treating cancer and hyperproliferative disorders
US7129072B1 (en) * 1999-08-30 2006-10-31 New York University Crystal of fibroblast growth factor receptor 1 in complex with fibroblast growth factor
US6420346B1 (en) * 2000-02-07 2002-07-16 Rappaport Family Institute For Research In The Medical Sciences Polynucleotides encoding MIP-1α, MCP-1, MIP-1β, Rantes and TNF-α, and methods for treating rheumatoid arthritis
WO2002044197A2 (en) * 2000-12-01 2002-06-06 Fish Eleanor N Cytokine receptor binding peptides
US20030166589A1 (en) * 2001-06-05 2003-09-04 Nathan Karin Method and pharmaceutical composition for the treatment of multiple sclerosis

Also Published As

Publication number Publication date
TNSN04200A1 (fr) 2007-03-12
FR2838444B1 (fr) 2016-01-01
CA2480996C (fr) 2016-06-21
ES2375053T3 (es) 2012-02-24
US20110171169A1 (en) 2011-07-14
US20100150957A1 (en) 2010-06-17
NZ536351A (en) 2007-03-30
US20120121627A1 (en) 2012-05-17
KR101101004B1 (ko) 2011-12-29
RU2326125C2 (ru) 2008-06-10
FR2838444A1 (fr) 2003-10-17
EP1492814A2 (de) 2005-01-05
EP1492814B1 (de) 2011-10-05
US20060241286A1 (en) 2006-10-26
EP2314311B1 (de) 2015-07-15
EP2314312A2 (de) 2011-04-27
EP2314311A3 (de) 2011-08-17
EP2314312A3 (de) 2011-08-31
MXPA04009841A (es) 2005-06-17
DK2314311T3 (en) 2015-10-12
EP2314311A2 (de) 2011-04-27
JP2005530723A (ja) 2005-10-13
US7393523B2 (en) 2008-07-01
WO2003084979A2 (fr) 2003-10-16
US7892529B2 (en) 2011-02-22
ZA200408451B (en) 2006-01-25
KR20040108709A (ko) 2004-12-24
US8147819B2 (en) 2012-04-03
CN1649898A (zh) 2005-08-03
AU2003260031B2 (en) 2009-10-29
ES2550030T3 (es) 2015-11-04
US20080260689A1 (en) 2008-10-23
US8529881B2 (en) 2013-09-10
US8277792B2 (en) 2012-10-02
RU2004132871A (ru) 2005-09-20
CA2480996A1 (fr) 2003-10-16
US7641895B2 (en) 2010-01-05
MA27191A1 (fr) 2005-01-03
US20120321652A1 (en) 2012-12-20
WO2003084979A3 (fr) 2004-04-08
IL164429A0 (en) 2005-12-18
SI2314311T1 (sl) 2015-12-31
AU2003260031A1 (en) 2003-10-20

Similar Documents

Publication Publication Date Title
SI2314311T1 (sl) Peptidi in njihova terapevtska uporaba
RU2010116278A (ru) Модифицированная константная область антитела
ATE162723T1 (de) Die induktion der antikörperantwort gegen eigene proteine mit hilfe fremder t-zellepitope
DE69935866D1 (de) Auf N-Formyl Methionyl Peptide basierendem Adjuvans für Impfstoffe
BR0209685A (pt) Derivado de um peptìdeo insulinotrópico e sais farmaceuticamente aceitáveis produzidos a partir do mesmo, método de produção de derivado de peptìdeo insulinotrópico e uso de um derivado de peptìdeo insulinotrópico e de sais farmaceuticamente aceitáveis
AR041173A1 (es) Aniticuerpo monoclonal anti- il- 1r1 humano terapeutico
DE3924746A1 (de) Erythropoietin (epo)-peptide und dagegen gerichtete antikoerper
CY1108282T1 (el) Χρηση λιποπεπτιδιου ή λιποπρωτεϊνης ως ανοσοενισχυτικο σε θεραπευτικο ή προφυλακτικο εμβολιασμο
WO2002004499A1 (en) Chemokine receptor modulators, production and use
EA200501550A1 (ru) СВЯЗАННЫЕ С МАТРИЦЕЙ ПЕПТИДОМИМЕТИКИ β-ШПИЛЕЧНОЙ СТРУКТУРЫ С АКТИВНОСТЬЮ АНТАГОНИСТОВ CXCR4
ATE238065T1 (de) Peptide zur verwendung in impfung und anregung von antikörperbildung gegen menschliches immunschwäche virus
DK0413383T3 (da) Mutanter af humant interleukin-3.
AU702294B2 (en) Proteins from mammalian liver and their use in oncology
JP2005530723A5 (de)
AU682687B2 (en) Botulinum toxin polypeptides and their use as vaccine enhancing agents
Jeannin et al. Immunogenecity and antigenicity of synthetic peptides derived from the mite allergen Der p I
Sakarellos-Daitsiotis et al. A new helicoid-type sequential oligopeptide carrier (SOCn) for developing potent antigens and immunogens
ATE422503T1 (de) Rekombinante polypeptide aus mycoplasma und impfstoffe
CN100540050C (zh) 含有白细胞介素-15(il-15)的疫苗组合物
US20040077835A1 (en) Chemokine receptor modulators, production and use
Herzbeck et al. Functional and Molecular Characterization of a Monoclonal Antibody against the 165–186 Peptide of Human 1β
Kurosaka et al. T-cell antigen receptor assembly and cell surface expression is not affected by treatment with T-cell antigen receptor-alpha chain transmembrane Peptide
AU2020416990A1 (en) Immunogenic conjugate intended to induce an immune response directed against interleukin-6
DE69123252D1 (de) Kreuzreaktive immunisierung gegen influenza
Kundu et al. Antiallergic activity of some novel oligopeptides related to immunoglobulin E

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties